Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Active not recruiting 2Unknown 1Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 5Neoplasms 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoking Cessation 1Sarcoma 1Peritoneal Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Lymphedema 1Locally Advanced Rectal Cancer 1HER2 Positive Esophagogastric Cancer 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Cachexia 1Advanced Esophageal Cancer 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × Combined Modality Therapy × Clear all
NCT07018427 2025-06-12

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Peking University Cancer Hospital & Institute

Active not recruiting
70 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06793306 2025-02-14

A Study Comparing the Differences Between Young and Non-young Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrolling by invitation
3,000 enrolled
Breast

Breast Neoplasms

NCT05228951 2022-09-13

Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

Shengjing Hospital

Phase 2 Recruiting
12 enrolled
Breast

Breast Neoplasms

NCT04486911 2022-08-02

Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

Shengjing Hospital

Phase 2 Active not recruiting
89 enrolled
Breast

Breast Neoplasms

NCT02165696 2014-06-17

LYMPHATIC

University of Malaga

Phase NA Unknown
44 enrolled
Breast

Breast Neoplasms, Lymphedema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡